CUDC-101: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 25 patients showed that 275 mg/m 2 IV CUDC-101 produced 1 partial response in a gastric cancer patient, while 150 mg/m 2 CUDC-101 led to 1 case o...